Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCA-0061 in Atopic Healthy Participants and Peanut Allergy
NCT07701954Phase 1Recruiting
- Sponsor
- Lycia Therapeutics
- Start
- Jun 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LCA-0061 in atopic disease and peanut allergy (4 arms), sponsored by Lycia Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events at Day 93, Treatment-Emergent Adverse Events leading to discontinuation at Day 93 and 2 more. Started Jun 2026; status: recruiting.
02
Drugs
LCA-0061
03
Conditions
atopic diseasepeanut allergy
Beyond the preview
Go deeper on NCT07701954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07701954.